Free Trial

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Ionis Pharmaceuticals logo with Medical background

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nineteen research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $60.65.

A number of equities research analysts recently commented on IONS shares. William Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Royal Bank of Canada reissued an "outperform" rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday, January 15th. Wells Fargo & Company lowered their target price on Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a research note on Thursday, November 7th. Needham & Company LLC reissued a "buy" rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Finally, Piper Sandler lowered their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th.

View Our Latest Analysis on IONS

Ionis Pharmaceuticals Price Performance

IONS stock traded up $1.53 during midday trading on Friday, hitting $33.17. The company's stock had a trading volume of 1,594,392 shares, compared to its average volume of 1,660,474. Ionis Pharmaceuticals has a 12 month low of $31.03 and a 12 month high of $52.34. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $5.24 billion, a price-to-earnings ratio of -13.59 and a beta of 0.35. The company has a 50 day moving average of $34.94 and a two-hundred day moving average of $39.84.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,194 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the completion of the transaction, the executive vice president now owns 33,713 shares in the company, valued at approximately $1,278,396.96. The trade was a 3.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Brett P. Monia sold 6,630 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the sale, the chief executive officer now directly owns 167,393 shares in the company, valued at $6,369,303.65. This trade represents a 3.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,425 shares of company stock worth $2,438,097. 2.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nicollet Investment Management Inc. grew its holdings in Ionis Pharmaceuticals by 1.5% during the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company's stock worth $817,000 after acquiring an additional 294 shares during the period. Amalgamated Bank lifted its holdings in shares of Ionis Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company's stock worth $399,000 after acquiring an additional 300 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock valued at $27,000 after acquiring an additional 303 shares during the last quarter. Itau Unibanco Holding S.A. increased its position in shares of Ionis Pharmaceuticals by 40.9% during the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company's stock valued at $43,000 after buying an additional 314 shares during the period. Finally, Bleakley Financial Group LLC grew its holdings in Ionis Pharmaceuticals by 2.1% in the third quarter. Bleakley Financial Group LLC now owns 16,678 shares of the company's stock worth $668,000 after purchasing an additional 338 shares during the period. 93.86% of the stock is currently owned by institutional investors.

About Ionis Pharmaceuticals

(Get Free Report

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Recommended Stories

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?

Before you consider Ionis Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.

While Ionis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines